Cancer BiologybioRxivPreprint
KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma
Nina Weichert‐Leahey, Alla Berezovskaya, Mark W. Zimmerman…·Alfred Thomas Look
This study shows that inhibiting KAT6A/B with PF-9363 enhances retinoid efficacy and improves GD2-targeted immunotherapy in neuroblastoma.
2 citations